Cell line · CVCL_0060
Papers232
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 232
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long non-coding RNA prompts immune-related adverse events risk and immunotherapy response in pan-cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reoviridae-derived short trimerization domain for stabilizing homo-trimerization of vaccine immunogens and therapeutic proteins. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sinensetin Induces Oxidative Stress-Mediated Apoptosis in Non-Small Cell Lung Cancer Cells by Suppressing Nrf2/ARE-Dependent Antioxidant Defense. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design and Synthesis of Novel Caudatin Derivatives Containing Arylacryloyl and Quinolyl Substituents With Anticancer Activity. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metformin Inhibits Ferroptotic Cell Death by Suppressing Cysteine Deprivation-Induced Mitochondrial Dysfunction. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the EpCAM-AXL axis to overcome drug resistance in lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Impact of Combretastatin A-4 on Cancer Cells and Circulating Tumor Cells (CTCs): A Multi-Assay Approach. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer. | Cancer Drug Resist | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HRAS promotes mutant NRAS-driven transformation with codon and allele specificity. | Sci Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K. | NPJ Vaccines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The lncRNA, CyKILRb acts as a ceRNA for tumor suppressive microRNA to augment oncogenic phenotype via induction of PIK3R2/PI3K/AKT axis. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell and Bulk Transcriptomic Integration Reveals an Adverse SPP1 Inflammatory TAM State and INHBA as a Candidate Biomarker in Non-Small Cell Lung Cancer Immunotherapy. | Int J Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0060/papers